Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis: A Randomized Controlled Trial | Nephrology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
US Renal Data System.  USRDS 1994 Annual Data ReportBethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1994.
2.
Woodrow G, Oldroyd B, Turney J, Tompkins L, Brownjohn A, Smith M. Whole body and regional body composition in patients with chronic renal failure.  Nephrol Dial Transplant.1996;11:1613-1618.Google Scholar
3.
Pollock C, Allen B, Warden R.  et al.  Total-body nitrogen by neutron activation in maintenance dialysis.  Am J Kidney Dis.1990;16:38-45.Google Scholar
4.
Coles G. Body composition in chronic renal failure.  QJM.1972;41:25-47.Google Scholar
5.
Hakim R, Levin N. Malnutrition in hemodialysis patients.  Am J Kidney Dis.1993;21:125-137.Google Scholar
6.
Lazarus J. Nutrition in hemodialysis patients.  Am J Kidney Dis.1993;21:99-105.Google Scholar
7.
Kopple J. Effect of nutrition on morbidity and mortality in maintenance dialysis patients.  Am J Kidney Dis.1994;24:1002-1009.Google Scholar
8.
Lowrie E, Lew N. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.  Am J Kidney Dis.1990;15:458-482.Google Scholar
9.
Mulligan K, Grunfeld C, Hellerstein M, Neese R, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection.  J Clin Endocrinol Metab.1993;77:956-962.Google Scholar
10.
Tayek J, Brasel J. Growth hormone administration decreases urea nitrogen losses in malnourished cancer patients [abstract].  Clin Res.1992;40:95A.Google Scholar
11.
Manson JM, Wilmore D. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding.  Surgery.1986;100:188-197.Google Scholar
12.
Ziegler T, Lazarus JM, Young L, Hakim R, Wilmore D. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis.  J Am Soc Nephrol.1991;2:1130-1135.Google Scholar
13.
Schulman G, Wingard R, Hutchison R, Lawrence P, Hakim R. The effects of recombinant human growth hormone and intradialysis parenteral nutrition in malnourished hemodialysis patients.  Am J Kidney Dis.1993;21:527-534.Google Scholar
14.
Ikizler T, Wingard R, Breyer J, Schulman G, Parker R, Hakim R. Short-term effects of recombinant human growth hormone in CAPD patients.  Kidney Int.1994;46:1178-1183.Google Scholar
15.
Bhasin S, Storer T, Berman N.  et al.  The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.  N Engl J Med.1996;335:1-7.Google Scholar
16.
Sargent J. Control of dialysis by a single-pool urea model: the National Cooperative Dialysis Study.  Kidney Int.1983;13(suppl):S19-S25.Google Scholar
17.
American College of Sports Medicine.  Guidelines for Exercise Testing and Prescription. 4th ed. Philadelphia, Pa: Lea & Febiger; 1991.
18.
Campbell A, Converse P, Rodgers W. The Quality of American LifeNew York, NY: Russell Sage Foundation; 1976.
19.
Bergner M, Bobbit R, Carter W, Gilson B. The Sickness Impact Profile: development and final revision of a health status measure.  Med Care.1981;19:787-805.Google Scholar
20.
McNair D, Lorr M, Droppleman L. EITS Manual for the Profile of Mood StatesSan Diego, Calif: Educational and Industrial Testing Service; 1971.
21.
Botero D, Danon M, Brown R. Symptomatic non-insulin-dependent diabetes mellitus during therapy with recombinant human growth hormone.  J Pediatr.1993;123:590-592.Google Scholar
22.
Kollind M, Adamson U, Lins P, Efendic S. Diabetogenic action of GH and cortisol in insulin-dependent diabetes mellitus: aspects of the mechanisms behind the Somogyi phenomenon.  Horm Metab Res.1987;19:156-159.Google Scholar
23.
Lindholm D, Fisher J, Vieira J, Dombeck DH, Bemal G, Lerthora J. Clinical effects of oral fluoxymesterone in patients with dialysis-controlled uremia.  Trans Am Soc Artif Intern Organs.1973;19:475-483.Google Scholar
24.
Hurley B, Seals D, Hagberg J.  et al.  High-density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use.  JAMA.1984;252:507-513.Google Scholar
25.
Thompson P, Cullinane E, Sady S.  et al.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.  JAMA.1989;261:1165-1168.Google Scholar
26.
Glazer G, Suchman A. Lack of demonstrated effect of nandrolone on serum lipids.  Metabolism.1994;43:204-210.Google Scholar
27.
Hendler E, Goffinet J, Ross S, Longnecker R, Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis.  N Engl J Med.1974;291:1046-1051.Google Scholar
28.
Teruel J, Lasuncion M, Rivera M.  et al.  Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients.  Am J Kidney Dis.1997;29:569-575.Google Scholar
29.
Lippi G, Guidi G, Ruzzenente O, Braga V, Adam S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis.  Scand J Clin Lab Invest.1997;57:507-512.Google Scholar
30.
Cressman M, Heyka R, Paganini E, O'Neil J, Skibinski C, Hoff H. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients.  Circulation.1992;86:475-482.Google Scholar
31.
Kronenberg F, Utermann G, Dleplinger H. Lipoprotein(a) in renal disease.  Am J Kidney Dis.1996;27:1-25.Google Scholar
32.
Bartens W, Nauck M, Schollmeyer P, Wanner C. Elevated lipoprotein(a) and fibrinogen levels [corrected] increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients.  Perit Dial Int.1996;16:27-33.Google Scholar
33.
Avram M, Sreedhara R, Patel N, Chattoopadhyay J, Thu T, Fein P. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients?  Adv Perit Dial.1996;12:266-271.Google Scholar
34.
Bradley J, Anderson J, Evans D, Cowley A. Impaired nutritive skeletal muscle blood flow in patients with chronic renal failure.  Clin Sci.1990;79:239-245.Google Scholar
35.
Painter P, Messer D, Widener C, Zimmerman S. Response to graded exercise testing in patients treated with CAPD.  Perit Dial Bull.1984;4(suppl):S94-S97.Google Scholar
36.
Painter P, Messer-Rehak D, Hanson P, Zimmerman S, Glass N. Exercise capacity in hemodialysis, CAPD, and renal transplant patients.  Nephron.1986;42:47-51.Google Scholar
37.
Moore G, Brinker K, Stray-Gundersen J, Mitchell J. Determinants of VO2peak in patients with end-stage renal disease: on and off dialysis.  Med Sci Sports Exerc.1993;25:18-23.Google Scholar
38.
Gutman R, Stead W, Robinson R. Physical activity and employment status of patients on maintenance dialysis.  N Engl J Med.1981;304:309-313.Google Scholar
39.
Ifudu O, Paul H, Mayers J.  et al.  Pervasive failed rehabilitation in center-based maintenance hemodialysis patients.  Am J Kidney Dis.1994;23:394-400.Google Scholar
40.
Churchill D, Torrance G, Taylor D.  et al.  Measurement of quality of life in end-stage renal disease: the time trade-off approach.  Clin Invest Med.1987;10:14-20.Google Scholar
Original Contribution
April 14, 1999

Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Divisions of Nephrology (Dr Johansen) and Endocrinology (Drs Mulligan and Schambelan), Department of Medicine, San Francisco General Hospital, University of California, San Francisco.

JAMA. 1999;281(14):1275-1281. doi:10.1001/jama.281.14.1275
Abstract

Context Patients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and strength in healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated.

Objective To assess the effects of an anabolic steroid, nandrolone decanoate, on lean body mass (LBM), functional status, and quality of life in dialysis patients.

Design Randomized, double-blind, placebo-controlled trial conducted between April 1996 and July 1997.

Setting Hospital-based outpatient dialysis unit.

Patients Twenty-nine patients undergoing dialysis for at least 3 months.

Intervention Nandrolone decanoate, 100 mg (n = 14), or placebo (n = 15) by intramuscular injection once a week for 6 months.

Main Outcome Measures Weight, LBM, fatigue, grip strength, walking and stair-climbing times, and treadmill performance after 3 and 6 months of treatment.

Results Lean body mass increased significantly in patients given nandrolone compared with patients given placebo (mean change [SD], +4.5 [2.3] kg; P<.001 compared with baseline). This effect was significantly greater than the change in LBM in the placebo group (mean change [SD], +1.9 [1.6] kg; P = .003 compared with baseline; P = .005 compared with nandrolone group). Serum creatinine levels increased in the nandrolone group (+168 [203] mmol/L [1.9 {2.3} mg/dL]; P = .02) but not in the placebo group (−4.0 [177] mmol/L [0.04 {2.0} mg/dL]; P = .95), suggesting an increase in muscle mass. Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the nandrolone group, while those in the placebo group increased from 38.7 to 42.1 seconds (P = .05). Peak oxygen consumption increased in the individuals in the nandrolone group who performed treadmill tests, but not to a statistically significant degree. Grip strength did not change in either group.

Conclusions Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis.

×